Paclitaxel in the treatment of ovarian cancer.docVIP

 PAGE \* MERGEFORMAT 17 Paclitaxel in the treatment of ovarian cancer Paclitaxel (taxol) is a natural plant product. In 1963, the first West Coast from the Pacific yew tree bark in the forests of the separation and extraction, because of their scarcity, and difficult to dissolve in water, the source characteristics, clinical application has been slow. In 1979, paclitaxel was found to promote cell with tubulin polymerization, solidification into a bundle and to prevent its unique mechanism of depolymerization, which leads to people’s attention [1]. In 1983, the United States National Cancer Center (NIC) began clinical trials research; in 1992, the U.S. Food and Drug Administration approval of Taxol for the treatment of metastatic ovarian cancer. In 1994, the U.S. companies were allowed to Bristol paclitaxel for China. Taxol studies to become a hot 90’s antitumor drugs issues. 1, mechanism of action and metabolism of paclitaxel Taxol is a diterpenoid compound, relative molecular mass of 853.9, melting point 213 ~ 216 ℃ , a highly lipophilic, insoluble in water [2]. Taxol-specific effect on the cell cycle G2 phase and M phase, so that microtubules in the mitotic spindle and the spindle can not form when the wire, to prevent tumor cell division and reproduction. Taxol is also acting on macrophages of tumor necrosis factor (TNF) receptor, triggers the release of interleukin (IL) -1, TNF-2, IL-6, interferon (IFN) -1, IFN-2, right tumor cells from destruction or inhibition of [3]. Paclitaxel metabolism in line with nonlinear saturation distribution and to exclude two-compartment model [4,5]. Some scholars have found that Taxol cosolvent - polyoxyethylene castor oil may be caused by non-linear pharmacokinetics of the material [6]. Into the blood of taxol, 90% of plasma proteins or tissue protein binding and specificity of the enzyme in the liver microsomal P-450 transfer into non-toxic product of 6 β -hydroxy-paclitaxel, which is an important means of detoxificatio